Search

Displaying results 1091 - 1100 of 7536 in total
  1. Drug

    Vasopressin

    go.drugbank.com/drugs/DB00067
    ApprovedInvestigational

    [A228013] Despite a wide variety of functions, exogenous vasopressin is primarily used to control blood pressure during systemic shock by increasing vasoconstriction and renal fluid reuptake by acting … [A228013] It is currently marketed under the trademark VASOSTRICT® by PAR Pharmaceuticals.[L31413]

  2. Drug

    Fusidic acid

    go.drugbank.com/drugs/DB02703
    ApprovedInvestigational

    It is often used topically in creams and eyedrops but is available in systemic formulations including tablets and injections. … (From Merck Index, 11th ed) It acts by inhibiting translocation during protein synthesis.

    Mixtures: ACELER-CO
  3. Drug

    Cryptenamine

    go.drugbank.com/drugs/DB00785
    Approved

    It has been used in the treatment of hypertension but has largely been replaced by drugs with fewer adverse effects. … Cryptenamine has a marked and re-producible depressor effect when given intravenously to hypertensive patients, however the mechanism of action is not known.

  4. Drug

    Ioxitalamic acid

    go.drugbank.com/drugs/DB13444
    ApprovedWithdrawn

    [A33006] Ioxitalamic acid in the salt forms of sodium and meglumine was developed by Liebel-Flarshem Canada Inc and approved by Health Canada in 1995. … [A27209] It is a first-generation contrast media formed by an ionic monomer with a high osmolarity of 1500-1800 mOsm/kg.

  5. Drug

    Trandolapril

    go.drugbank.com/drugs/DB00519
    ApprovedInvestigational

    Trandolapril is a non-sulhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. … Trandolapril may be used to treat mild to moderate hypertension, to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction, as an adjunct treatment

    Categories: Agents Acting on the Renin-Angiotensin System
  6. Drug

    Pexidartinib

    go.drugbank.com/drugs/DB12978
    ApprovedInvestigational

    [L7901] Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue. … Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor

  7. Drug

    Technetium Tc-99m tetrofosmin

    go.drugbank.com/drugs/DB09160
    Approved

    [A31592] Technetium Tc-99m tetrofosmin was developed by GE Healthcare and FDA approved on February 9, 1996. … The radioisotope, technetium-99m, is chelated by two 1,2-bis[di-(2-ethoxyethyl)phosphino]ethane ligands which belong to the group of diphosphines and which are referred to as tetrofosmin.

  8. Drug

    Pentetic acid

    go.drugbank.com/drugs/DB14007
    ApprovedInvestigational

    [L2242] DPTA was developed by the pharmaceutical company CIS US and FDA approved on April 14, 2004.[L1469] … DTPA, along with its calcium and zinc trisodium salts, are the only FDA approved agents for the treatment of internal contamination by transuranics.

  9. Drug

    Miglitol

    go.drugbank.com/drugs/DB00491
    Approved

    Unlike other drugs of the same class, miglitol is not metabolized and the unmetabolized drug is excreted by the kidneys. … monosaccharides which can be absorbed by the body.

  10. Drug

    Osilodrostat

    go.drugbank.com/drugs/DB11837
    ApprovedInvestigational

    [L12123] It has undergone phase II clinical trials for the treatment of solid tumours, hypertension, and heart failure, but development for these indications was discontinued by Novartis in January 2013 … has not been curative.